Nozomu Machida

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system

Tomohiro Yamaguchi, Nozomu Machida, Chigusa Morizane et al. · Cancer Science · 2014 · 235 citations · Full text

Systemic Chemotherapy, Advanced Neuroendocrine Carcinoma, Gastroenterology +17

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

Nozomu Fuse, Yasutoshi Kuboki, Takeshi Kuwata et al. · Gastric Cancer · 2015 · 112 citations · Full text

Prognostic Impact, Esophageal Cancer, Overall Survival +9

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 85 citations · Full text

Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison

Toshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi et al. · Clinical Colorectal Cancer · 2016 · 74 citations

Regorafenib Versus Trifluridine/tipiracil, Surgical Oncology, Retrospective Comparison +8